POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, and Sumitomo Dainippon Pharma Co., Ltd., announced that a new drug application for TWYMEEG® Tablets 500mg3 : Imeglimin hydrochloride), for the treatment of type 2 diabetes, was approved in Japan on June 23.
June 23, 2021
· 10 min read